健康教育配合利拉鲁肽单药治疗新诊断超重2型糖尿病患者的临床分析

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (43 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the treatment methods of health education with Liraglutide monotherapy treatment of newly diagnosed overweight patients with type 2 diabetes,which can further provide the theoretical basis and reference for clinical application.Methods30 cases of overweight patients with type 2 diabetes from June 2014 to May 2016 in our hospital were selected as the research object,they were divided into education united group(n=15)and Liraglutide group (n=15)using the random number table method.Liraglutide group was given a separate Liraglutide monotherapy, subcutaneous injection,18 mg/d,injection 12 weeks in a row,education united group was given Liraglutide monotherapy and health education.Then the difference of blood pressure,body weight,body mass index (BMI),low density lipoprotein cholesterol(LDL-C),triglyceride(TG),total cholesterol(TC),fasting C peptide(FC-P),HOMA-IR(CP),HOMA IR islet(CP), glycosylated hemoglobin(HbA1c),postprandial 2 h blood glucose(2 h PG),fasting plasma glucose(FPG),and other indicators was compared between the two groups.ResultsThe FPG,2 h PG,HbA1c,weight,BMI,SB,FC-P,HOMA islet,HOMA-IR, TC,TG and LDL-C were significantly lower compard with before treatment,and education united group had more significantly reduce compared with Liraglutide group,the difference value of before and after treatment in the two groups had statistically significant difference(P<0.05).ConclusionThe combination with health education and Liraglutide is a kind of effective treatment to overweight type 2 diabetes patients,and superior than the Liraglutide monotherapy,because it can effectively control overweight type 2 diabetes patients with body weight,lower blood pressure,FPG,2 h PG,and it plays a role in lipid regulation as well.

Key words： Health education Liraglutide Overweight type 2 diabetes

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Hai-yan
	LIU Hui-xia

Cite this article:

WANG Hai-yan,LIU Hui-xia. Clinical analysis of health education with Liraglutide monotherapy treatment of newly diagnosed overweight patients with type 2 diabetes[J]. 中国当代医药, 2017, 24(11): 51-54.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I11/51

[1]	包玉倩，贾伟平.糖尿病治疗的新药物与新策略[J].中国新药与临床杂志，2011，30（6）：401-402.
[2]	王昕，张原.2010年版中国2型糖尿病防治指南解读[J].中老年保健，2011，27（7）：16-17.
[3]	李枝萍，刘军，徐婷婷，等.我国 2型糖尿病的流行病学及危险因素研究现状[J].西南军医，2010，12（4）：754-756.
[4]	范慧，张鹏睿，徐援.2型糖尿病合并非酒精性脂肪肝与胰岛素抵抗及心血管病变发生的关系研究[J].中国全科医学，2011，14（1B）：147-150.
[5]	周瑾，卢逢娣.肥胖或超重2型糖尿病患者护理干预的研究进展[J].护士进修杂志，2011，26（4）：303-305.
[6]	傅晓莹，杨华章，邝建，等.利拉鲁肽治疗 2型糖尿病的疗效及安全性[J].广东医学，2013，34（23）：3561-1563.
[7]	杨文英.人GLP-1类似物利拉鲁肽的最新研究进展[J].中华内分泌代谢杂志，2010，25（9）：840-843.
[8]	邹大进.人胰升糖素样肽1类似物利拉鲁肽减轻2型糖尿病患者体重的作用[J].中华内分泌代谢杂志，2011，26（8）：703-706.
[9]	付阿丹，鲁桂鸣，杨静，等.糖尿病健康教育路径的临床应用效果评价[J].中国全科医学，2011，14（10A）：3268-3270.
[10]	马静.全程健康教育模式在糖尿病护理管理中的作用[J].护士进修杂志，2012，27（23）：2169-2171.
[11]	潘长玉，尹士男.胰岛素抵抗2型糖尿病发病机制的重要因素[J].中华内分泌代谢杂志，2000，15（1）：56-57.
[12]	张良满，喻翠玲，徐蓉，等.2型糖尿病胰岛素强化治疗患者的低血糖原因分析及护理[J].中华护理杂志，2005，40（7）：518-519.
[13]	祝方，纪立农.新诊断2型糖尿病患者早期胰岛素强化治疗的随访研究[J].中国糖尿病杂志，2009，17（4）：261-263.
[14]	张红.利拉鲁肽治疗2型糖尿病的临床观察[J].中外医疗，2012，28（69）：101-102.
[15]	陈忻，翟所迪.利拉鲁肽用于治疗2型糖尿病临床研究现状[J].中国药学杂志，2011，46（21）：1685-1687.
[16]	Thompson AM，Trujillo JM.Dulaglutide：the newest GLP-1 receptor agonist for the management of type 2 diabetes[J]. Ann Pharmacother，2015，49（3）：351-359.